Sulfonylurea receptors and mechanism of sulfonylurea action

Experimental and Clinical Endocrinology and Diabetes

Volumn 104, Issue 1, 1996, Pages 1-9

  Panten, U ^a   Schwanstecher, M ^a   Schwanstecher, C ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

ATP sensitive K+ channels; Extrapancreatic actions; Insulin releasing antidiabetics; Sulfonylurea receptors

Indexed keywords

DRUG RECEPTOR; INSULIN; ORAL ANTIDIABETIC AGENT; POTASSIUM CHANNEL; SULFONYLUREA;

BINDING SITE; CARDIOVASCULAR DISEASE; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE MUTATION; HYPERINSULINISM; INSULIN RELEASE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW;

EID: 0030052995     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211414     Document Type: Review

References (100)

1. Aguilar-Bryan L, Nelson DA, Vu QA, Humphrey MB, Boyd III AE: Photoaffinity labeling and partial purification of the β cell sulfonylurea receptor using a novel, biologically active glyburide analog. J Biol Chem 265: 8218-8244, 1990.
2. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement IV JP, Boyd III AE, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, Nelson DA: Cloning of the β cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. Science 268: 423-426, 1995.
3. Akiyoshi M, Kakei M, Nakazaki M, Tanaka H: A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. Am J Physiol 268: E185-E193, 1995.
4. Ashcroft SJH: The β cell sulfonylurea receptor. Diab Nutr Metab 7: 149-163, 1994.
5. Ashcroft SJH, Ashcroft FM: Properties and functions of ATP-sensitive K-channels. Cell Signal 2: 197-214, 1990.
6. Ashcroft SJH, Ashcroft FM: The sulfonylurea receptor. Biochim Biophys Acta 1175: 45-59, 1992.
7. Ashcroft FM, Rorsman P: Electrophysiology of the pancreatic β-cell. Prog Biophys Molec Biol 54: 87-143, 1991.
8. Ashcroft FM, Harrison DE, Ashcroft SJH: Glucose induces closure of single potassium channels in isolated rat pancreatic β-cells. Nature 312: 446-448, 1984.
9. ATP channel. Nature 370: 456-459, 1994.
10. Baker L, Thornton PS, Stanley CA: Management of hyperinsulinism in infants. J Pediatr 119: 755-757, 1991.
11. Bond CT, Ämmälä C, Ashfield R, Blair TA, Gribble F, Khan RN, Lee K, Proks P, Rowe ICM, Sakura H, Ashford MJ, Adelman JP, Ashcroft FM: Cloning and functional expression of the cDNA encoding an inwardly-rectifying potassium channel expressed in pancreatic β-cells and in the brain. FEBS Lett 367: 61-66, 1995.
12. Bouman PR, Gaarenstroom JH: Stimulation by carbutamide and tolbutamide of insulin release from rat pancreas in vitro. Metabolism 10: 1095-1099, 1961.
13. 3H-glibenclamide in pancreatic islet cells. Diabetologia 29: 259-261, 1986.
14. + channels in pancreatic B-cells. Nature 311: 271-273, 1984.
15. Coore HG, Randle PJ: Regulation of insulin secretion studied with pieces of rabbit pancreas incubated in vitro. Biochem J 93: 66-78, 1964.
16. + channel: Expression cloning and molecular properties. Proc Natl Acad Sci USA 90: 10235-10239, 1993.
17. Dean PM, Matthews EK: Electrical activity in pancreatic islets cells. Nature 219: 389-390, 1968.
18. Doupnik CA, Davidson N, Lester HA: The inward rectifier potassium channel family. Curr Opin Neurobiol 5: 268-277, 1995.
19. Dunne MJ: Protein phosphorylation is required for diazoxide to open ATP-sensitive potassium channels in insulin (RINm5F) secreting cells. FEBS Lett 250: 262-266, 1989.
20. Dunne MJ, Kane C, Squires PE, James RFL, Johnson PRV, Lindley KJ: Defective B-cell ion channels may underlie neonatal nesidioblastosis in humans. Diabetologia 38: A15, 1995.
21. Edwards G, Weston AH: The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol 33: 597-637, 1993.
22. Ferner RE, Chaplin S: The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet 12: 379-401, 1987.
23. Ferner RE, Neil HAW: Sulphonylureas and hypoglycaemia. Br Med J 296: 949-950, 1988.
24. Findlay I: The effects of magnesium upon adenosine triphosphate-sensitive potassium channels in a rat insulin-secreting cell line. J Physiol (Lond) 391: 611-629, 1987.
25. + channels. J Biol Chem 263: 7933-7936, 1988.
26. Foster DW, Rubenstein AH: Hypoglycemia. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds): Harrison's principles of internal medicine. Thirteenth Edition. pp. 2000-2006, McGraw-Hill, New York, 1994.
27. 2+ influx. Endocrinology 134: 1395-1400, 1994.
28. Gaines KL, Hamilton S, Boyd III AE: Characterization of the sulfonylurea receptor on beta cell membranes. J Biol Chem 263: 2589-2592, 1988.
29. Garcia-Barrado MJ, Jonas JC, Gilon P, Henquin JC: No evidence for an alternative mechanism of stimulation of insulin secretion by sulphonylureas. Diabetologia 38: A107, 1995.
30. Garrino M-G, Schmeer W, Nenquin M, Meissner HP, Henquin JC: Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide. Diabetologia 28: 697-703, 1985.
31. 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics. Arzneimittelforsch 35: 707-712, 1985.
32. Glaser B, Chiu KC, Anker R, Nestorowicz A, Landau H, Ben-Bassat H, Shlomai Z, Kaiser N, Thornton PS, Stanley CA, Spielman RS, Gogolin-Ewens K, Cerasi E, Baker L, Rice J, Donis-Keller H, Permutt MA: Familial hyperinsulinism maps to chromosome 11p14-15.1, 30 cM centromeric to the insulin gene. Nature Genet 7: 185-188, 1994.
33. + channels: pharmacologic properties, regulation, and therapeutic potential. Drug Devel Res 28: 95-127, 1993.
34. 3H]glyburide, to neuronal and muscle preparations. J Pharmacol Exp Ther 257: 1162-1171, 1991.
35. Gromada J, Dissing S, Kofod H, Frøkjaer-Jensen J: Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in β TC3 cells and rat pancreatic beta cells. Diabetologia 38: 1025-1032, 1995.
36. Grover GJ: Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia. J Cardiovasc Pharmacol 24 (suppl 4): S18-S27, 1994.
37. Gylfe E, Hellman B, Sehlin J, Täljedal I-B: Interaction of sulfonylurea with the pancreatic B-cell. Experientia 40: 1126-1134, 1984.
38. Hearse DJ: Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc Res 30: 1-17, 1995.
39. Henquin JC: Tolbutamide stimulation and inhibition of insulin release: studies of the underlying ionic mechanisms in isolated rat islets. Diabetologia 18: 151-160, 1980.
40. Henquin JC: Regulation of insulin release by ionic and electrical events in B cells. Hormone Res 27: 168-178, 1987.
41. + channels may control glucose-induced electrical activity in pancreatic B-cells. Biochem Biophys Res Comm 156: 769-775, 1988.
42. 2+. Diabetes 39: 1457-1460, 1990.
43. Hirose H, Maruyama H, Seto Y, Ito K, Fujita T, Dan K, Kanda N, Saruta T, Kato R: Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic α- and β-cells: Comparative study with glibenclamide. Pharmacology 50: 175-181, 1995.
44. Ho K, Nichols CG, Lederer WJ, Lytton J, Vassilev PM, Kanazirska MV, Herbert SC: Cloning and expression of an inwardly rectifying ATP-regulated potassium channel. Nature 362: 31-38, 1993.
45. Inagaki N, Tsuura Y, Namba N, Masuda K, Gonoi T, Horie M, Seino Y, Mizuta M, Seino S: Cloning and functional characterization of a novel ATP-sensitive potassium channel ubiquitously expressed in rat tissues, including pancreatic islets, pituitary, skeletal muscle and heart. J Biol Chem 270: 5691-5694, 1995a.
46. ATP: An inward rectifier subunit plus the sulfonylurea receptor. Science 270: 1166-1170, 1995b.
47. 3H]glibenclamide in rat liver membranes. Eur J Pharmacol 284: 77-82, 1995.
48. + channels during anoxia: major differences between rat (newborn and adult) and turtle neurons. J Physiol (Lond) 448: 599-612, 1992.
49. Kaku K, Inoue Y, Kaneko T: Extrapancreatic effects of sulfonylurea drugs. Diab Res Clin Pract 28 (suppl): S105-S108, 1995.
50. Kaubisch N, Hammer R, Wollheim C, Renold AE, Offord RE: Specific receptors for sulfonylureas in brain and in a β-cell tumor of the rat. Biochem Pharmacol 31: 1171-1174, 1982.
51. ATP channel and sulphonylurea receptor in the rat clonal insulin-secreting cell line, CRI-D11. Proc R Soc Lond B 253: 225-231, 1993.
52. Kosmas EN, Levy RD, Hussain SNA: Acute effects of glyburide on the regulation of peripheral blood flow in normal humans. Eur J Pharmacol 274: 193-199, 1995.
53. + channels from aortic smooth muscle incorporated into planar lipid bilayers. Am J Physiol 261: H604-H609, 1991.
54. + currents recorded from an insulin-secreting cell line. Br J Pharmacol 97: 1039-1050, 1989.
55. 3H]glibenclamide. FEBS Lett 229: 355-359, 1988.
56. +-channel proteins. Nature 374: 135-141, 1995.
57. Kubo Y, Baldwin TJ, Jan YN, Jan LY: Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature 362: 127-133, 1993.
58. ATP channel by ADP and diazoxide requires nucleotide hydrolysis in mouse pancreatic β-cells. J Physiol (Lond) 463: 349-365, 1993.
59. Lazdunski M: ATP-sensitive potassium channels: An overview. J Cardiovasc Pharmacol 24 (suppl 4): S1-S5, 1994.
60. Loubatières A: The hypoglycemic sulfonamides: History and development of the problem from 1942 to 1955. Ann NY Acad Sci 71: 4-11, 1957a.
61. Loubatières A: The mechanism of action of the hypoglycemic sulfonamides: A concept based on investigations in animals and human beings. Ann NY Acad Sci 71: 192-206, 1957b.
62. Malaisse WJ, Malaisse-Lagae F, Mayhew DA, Wright PH: Effects of sulfonylureas upon insulin secretion by the rat's pancreas: In: Butterfield WJH, van Westering W (eds): Tolbutamide after ten years, pp 49-60, Excerpta Medica, Amsterdam, 1967.
63. Matthews EK: Electrophysiology of pancreatic islet β-cells. In: Poisner AM, Trifaro JM (eds) The Electrophysiology of the Secretory cell. pp 93-112, Elsevier, Amsterdam, 1985.
64. + channel by a non-sulfonylurea compound KAD-1229 in a pancreatic β-cell line, MIN 6 cell. Eur J Pharmacol 269: 293-298, 1994.
65. 125J-labeled glyburide analog. J Biol Chem 267: 14928-14933, 1992.
66. Nelson MT, Quayle JM: Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268: C799-C822, 1995.
67. Nichols CG, Lederer WJ: Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol 261: H1675-H1686, 1991.
68. Niki I, Ashcroft SJH: Possible involvement of protein phosphorylation in the regulation of the sulfonylurea receptor of a pancreatic β-cell line, HIT T15. Biochim Biophys Acta 1133: 95-101, 1991.
69. + channels in cardiac muscle. Nature 305: 147-148, 1983.
70. Ohnota H, Kobayashi M, Koizumi T, Katsuno K, Sato F, Aizawa T: In vitro insulinotropic action of a new non-sulfonylurea hypoglycemic agent, calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinyl-carbonyl) propionate dihydrate (KAD-1229), in rat pancreatic B-cells. Biochem Pharmacol 49: 165-171, 1995.
71. Ohnota H, Koizumi T, Tsutsumi N, Kobayashi M, Inoue S, Sato F: Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinyl carbonyl)propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exper Ther 269: 489-495, 1994.
72. Ozanne SE, Guest PC, Hutton JC, Hales CN: Intracellular localization and molecular heterogeneity of the sulphonylurea receptor in insulin-secreting cells. Diabetologia 38: 277-282, 1995.
73. Palatnick W, Meatherall RC, Tenenbein M: Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy. Arch Intern Med 151: 1859-1862, 1991.
74. Panten U, Burgfeld J, Goerke F, Rennicke M, Schwanstecher M, Wallasch A, Zünkler BJ, Lenzen S: Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochem Pharmacol 38: 1217-1229, 1989.
75. + channel in mouse pancreatic B-cells. Naunyn-Schmiedeberg's Arch Pharmacol 342: 566-574, 1990.
76. Panten U, Schwanstecher M, Schwanstecher C: Pancreatic and extrapancreatic sulfonylurea receptors. Horm Metab Res 24: 549-554, 1992.
77. Panten U, Schwanstecher M, Schwanstecher C: Mode of action of sulfonylureas. In: Kuhlmann J, Puls W (eds): Oral antidiabetics. Handbook of experimental pharmacology, Vol. 119. In press, Springer, Berlin, 1996.
78. Panten U, Zünkler BJ, Scheit S, Kirchhoff K, Lenzen S: Regulation of energy metabolism in pancreatic islets by glucose and tolbutamide. Diabetologia 29: 648-654, 1986.
79. + channel in insulin-secreting cells. J Biol Chem 262: 15840-15844, 1987.
80. + channel in mouse pancreatic β-cells. Br J Pharmacol 107: 87-94, 1992a.
81. + channel in mouse pancreatic B cells by their combined actions at inhibitory and stimulatory receptors. Mol Pharmacol 41: 480-486, 1992b.
82. + channel in mouse β-cells. Br J Pharmacol 111: 302-310, 1994a.
83. Schwanstecher M, Panten U: Protein phosphorylation regulates receptor binding of potassium channel openers in insulin secreting cells and cerebral cortex. Biol Chem Hoppe-Seyler 374: 151, 1993.
84. Schwanstecher M, Brandt C, Behrends S, Schaupp U, Panten U: Effect of MgATP on pinacidil-induced displacement of glibenclamide from the sulphonylurea receptor in a pancreatic β-cell line and rat cerebral cortex. Br J Pharmacol 106: 295-301, 1992c.
85. Schwanstecher M, Löser S, Chudziak F, Panten U: Identification of a 38-kDA high affinity sulfonylurea-binding peptide in insulin-secreting cells and cerebral cortex. J Biol Chem 269: 17768-17771, 1994b.
86. Schwanstecher M, Löser S, Rietze I, Panten U: Phosphate and thiophosphate group donating adenine and guanine nucleotides inhibit glibenclamide binding to membranes from pancreatic islets. Naunyn-Schmiedeberg's Arch Pharmacol 343: 83-89, 1991.
87. + channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets. Pharmacology 49: 105-111, 1994c.
88. Schwanstecher M, Schwanstecher C, Dickel C, Chudziak F, Moshiri A, Panten U: Location of the sulphonylurea receptor at the cytoplasmic face of the β-cell membrane. Br J Pharmacol 113: 903-911, 1994d.
89. Skeer JM, Dégano P, Coles B, Potier M, Ashcroft FM, Ashcroft SJH: Determination of the molecular mass of the native β-cell sulfonylurea receptor. FEBS Lett 338: 98-102, 1994.
90. + channels in arterial smooth muscle. Science 245: 177-180, 1989.
91. Sturgess NC, Ashford MLJ, Cook DL, Hales CN: The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 8453: 474-475, 1985.
92. +channel-opening drugs. Am J Physiol 269: C525-C545, 1995.
93. Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J: Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268: 426-429, 1995.
94. Thornton PS, Sumner AE, Ruchelli ED, Spielman RS, Baker L, Stanley CA: Familial and sporadic hyperinsulinism: Histopathological findings and segregation analysis support a single autosomal recessive disorder. J Pediatr 119: 721-724, 1991.
95. + channel in mouse pancreatic β-cells. Pflügers Arch 407: 493-499, 1986.
96. ATP-channel opening and arrhythmogenesis. J Cardiovasc Pharmacol 24 (suppl 4): S35-S40, 1994.
97. Yalow RS, Black H, Villazon M, Berson SA: Comparison of plasma insulin levels following administration of tolbutamide and glucose. Diabetes 9: 356-362, 1960.
98. Yao Z, Gross GJ: The ATP-dependent potassium channel: An endogenous cardioprotective mechanism. J Cardiovasc Pharmacol 24 (suppl 4): S28-S34, 1994.
99. Zini S, Ben-Ari Y, Ashford MLJ: Characterization of sulfonylurea receptors and the action of potassium channel openers on cholinergic neurotransmission in guinea pig isolated small intestine. J Pharmacol Exp Ther 259: 566-573, 1991.
100. + channels from pancreatic B-cells. FEBS Lett 239: 241-244, 1988.